FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

CBER Safety Labeling Changes SOPP

[ Price : $8.95]

CBER publishes a standard operating policy and procedure on Section 505 (o)(4) safety labeling changes to drugs approved by NDAs a...

After 12+ Years, FDA Approves Steroid Label Changes

[ Price : $8.95]

After 12+ years, FDA accepts a specific labeling change sought for glucocorticosteroids in a Public Citizen 2011 petition, while d...

FDA Clears Masimo OTC Pulse Oximeter

[ Price : $8.95]

FDA clears a Masimo 510(k) for its MightySat Medical, an over-the-counter fingertip pulse oximeter.

Insanitary Conditions at Madhu Instruments

[ Price : $8.95]

FDA warns New Delhi, India-based Madhu Instruments Private Limited that it is producing drugs in insanitary conditions.

CGMP Violations in Ningbo Poplar Records

[ Price : $8.95]

FDA warns Chinas Ningbo Poplar Daily-Use about CGMP violations in its manufacturing of over-the-counter drugs.

Information Technology Operating Plan Posted

[ Price : $8.95]

The FDA Office of Digital Transformation posts its new IT operating plan and its 2023 annual report.

FDA Approves Ipsens Pancreatic Cancer Drug

[ Price : $8.95]

FDA approves an Ipsen Biopharmaceuticals NDA for Onivyde (irinotecan liposome) for use in combination with oxaliplatin, fluorourac...

5-Year Debarment for Ross Lucien

[ Price : $8.95]

Federal Register notice: FDA issues an order debarring Ross Lucien for five years from importing any drug into the U.S.

Kalpen Patel Debarred by FDA

[ Price : $8.95]

Federal Register notice: FDA issues an order to permanently debar Kalpen D. Patel from providing services in any capacity to a per...

Data Monitoring Draft Guidance Released

[ Price : $8.95]

Federal Register notice: FDA releases a draft guidance entitled Use of Data Monitoring Committees in Clinical Trials.